<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686527</url>
  </required_header>
  <id_info>
    <org_study_id>35RC12_8974 AOMYOC</org_study_id>
    <nct_id>NCT03686527</nct_id>
  </id_info>
  <brief_title>Myocardial Function of the Setonis Aortic Valve Before and Beyond Valve Replacement</brief_title>
  <acronym>AOMYOC</acronym>
  <official_title>Myocardial Function of the Setonis Aortic Valve Before and Beyond Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study the consequences on heart muscle of the stenosis aortic valve before and after the
      replacement procedure, the repercussion on heart. Study the impact on the heart of &quot;sick&quot;
      valve can affect on &quot;well-being&quot; and prognosis in the year following the surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2018</start_date>
  <completion_date type="Actual">January 11, 2019</completion_date>
  <primary_completion_date type="Actual">January 11, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is a composite endpoint: all-cause death, cardiovascular hospitalization: cardiac decompensation, atrial fibrillation within 12 months of surgical or percutaneous aortic valve replacement.</measure>
    <time_frame>1 day of inclusion</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">277</enrollment>
  <condition>Myocardial Function of the Stenosis Aortic Valve Before and Beyond Valve Replacement</condition>
  <arm_group>
    <arm_group_label>Echocardiography</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI Fibrosis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>stenosis aortic valve</intervention_name>
    <description>The exams to be realized :
a clinical examination with blood pressure
a 12-lead surface electrocardiogram
a standard biological assessment including NTproBNP (Brain Natriuretic Peptide)
Transthoracic echocardiography at baseline and 12 months after the aortic valve intervention on the (according to recommendations)
a cardiac MRI looking for fibrosis myocardial</description>
    <arm_group_label>Echocardiography</arm_group_label>
    <arm_group_label>MRI Fibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with tight aortic stenosis with an indication of surgical treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  major patient freely accepting to participate in the study

          -  non-opposition signed

          -  aortic surface &lt;1cm² or &lt;0.6cm² / m² of indication surgical restraint

          -  oriented to short interventional management surgical term

          -  LVEF Left ventricular ejection fraction&gt; 50%

          -  In the subgroup &quot;MRI-fibrosis&quot;, absence of indication for performing MRI

        Exclusion Criteria:

          -  patient under guardianship, curatorship or safeguard of justice

          -  minor patient

          -  pregnant woman

          -  patient with significant polyvalvulopathy for which it is from the start programmed
             more than aortic valve replacement

          -  patient with severe coronary artery disease requiring revascularization

          -  allergy to the contrast product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

